RDY Negative Sentiment Score: 40/100
Dr. Reddy's Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500 034, Telangana, India. CIN : L85195TG1984PLC004507 Tel : +91 40 4900 2900 Fax : +91 40 4900 2999 Email : mail@drreddys.com www.drreddys.co
Saturday, October 28, 2023 1 min read
Key Takeaway: Dr. Reddy's Laboratories Limited has announced the completion of a routine cGMP inspection by the USFDA at its formulations facility in Bachupally, Hyderabad. The inspection, which took place from October 19 to October 27, 2023, resulted in the issuance of a Form 483 containing ten observations. The company is required to address these observations within a specified timeline. This development may impact the company's operations and regulatory standing.
Full Press Release Details
National Stock Exchange of India Ltd. (Scrip Code: DRREDDY-EQ)
BSE Limited (Scrip Code: 500124)
New York Stock Exchange Inc. (Stock Code: RDY)
NSE IFSC Ltd (Stock Code: DRREDDY)
This is to inform that the United States Food &
Drug Administration (USFDA) completed a routine cGMP inspection at our formulations manufacturing facility (FTO-3) in Bachupally, Hyderabad.
The inspection was conducted from October 19, 2023 to October 27, 2023. We have been issued a Form 483 with ten observations, which we
will address within the stipulated timeline.
For Dr. Reddy's Laboratories Limited
Company Secretary, Compliance Officer and Head-CSR